Related Experiment Video
Updated: Feb 12, 2026

Handheld Metal Detector Screening for Metallic Foreign Body Ingestion in Children
Published on: September 11, 2018
Validation of the Proxy Version of Symptom Screening in Pediatrics Tool in Children Receiving Cancer Treatments
Shannon Hyslop1, L Lee Dupuis2, Christina Baggott3
1Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, Toronto, Ontario, Canada.
Insights
The Symptom Screening in Pediatrics Tool (SSPedi) is a reliable and valid proxy-report for assessing symptoms in children with cancer and following HSCT. This tool aids in symptom assessment when children cannot self-report.
Area of Science:
- Pediatric Oncology
- Hematopoietic Stem Cell Transplantation
- Clinical Assessment Tools
Background:
- Accurate symptom assessment is crucial for pediatric cancer and HSCT patients.
- Proxy-reporting tools are needed when children cannot self-report symptoms due to illness or treatment.
- The Symptom Screening in Pediatrics Tool (SSPedi) is a potential proxy-report instrument.
Purpose of the Study:
- To evaluate the interrater reliability and validity of the proxy-report Symptom Screening in Pediatrics Tool (SSPedi).
- To assess SSPedi's utility in children with cancer and pediatric hematopoietic stem cell transplant (HSCT) recipients.
- To describe the interrater reliability of individual SSPedi items.
Main Methods:
- Recruited 439 child-parent/guardian pairs across two groups: more symptomatic (active cancer treatment, hospitalized) and less symptomatic (maintenance or completed treatment).
- Assessed convergent validity by comparing proxy-reported SSPedi scores with child self-reported scales for mucositis, nausea/vomiting, and pain.
- Evaluated discriminant validity by comparing SSPedi scores between symptomatic groups and assessed interrater reliability for each SSPedi item.
Main Results:
- The mean SSPedi score difference between more and less symptomatic groups was 8.2 (95% CI 6.6-9.8).
- All hypothesized validity relationships were observed.
- Interrater reliability for SSPedi items ranged from 0.34 (problems with thinking) to 0.80 (diarrhea).
Conclusions:
- The proxy-report SSPedi demonstrates reliability and validity in children aged 8-18 with cancer and HSCT recipients.
- Findings support the use of SSPedi in clinical settings for children unable to self-report symptoms.
- Future research should focus on integrating proxy-reported symptom assessment into routine clinical practice.
Objectives:
Primary objectives were to evaluate the interrater reliability and validity of proxy-report Symptom Screening in Pediatrics Tool (SSPedi) in children with cancer and pediatric hematopoietic stem cell transplant (HSCT) recipients. Secondary objective was to describe the interrater reliability of each SSPedi item.
Methods:
Respondents were children aged eight to 18 years with cancer or HSCT recipients, and their parents or guardians. We enrolled two pediatric respondent groups. The more symptomatic group was receiving active treatment for cancer, admitted to hospital, and expected to be in a hospital three days later. The less symptomatic group either was in maintenance therapy for acute lymphoblastic leukemia or had completed cancer treatments. Convergent validity was evaluated by comparing proxy-reported mucositis, nausea and vomiting, pain, and total SSPedi scores, with child self-reported validated scales, and we hypothesized fair correlations. Discriminant validity was evaluated by comparing proxy-reported total SSPedi scores between groups. Interrater reliability of each SSPedi item was evaluated.
Results:
Four hundred thirty-nine child and parent or guardian pairs were recruited. Mean difference in proxy-reported SSPedi scores between the more and less symptomatic groups was 8.2, 95% CI 6.6-9.8. All hypothesized relationships among measures were observed. Intraclass correlation coefficients for SSPedi items ranged from 0.34 (problems with thinking) to 0.80 (diarrhea).
Conclusion:
Proxy-report SSPedi is reliable and valid in children aged 8 years to 18 years with cancer and HSCT recipients. Future work should support proxy-reported symptom assessment in clinical settings where children are not able to self-report or communicate bothersome symptoms.
Related Concept Videos
Treatment Resistant Cancers
Reliability and Validity
Receiver Operating Characteristic Plot
Diabetes: Symptoms, Diagnosis, and Complications
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Data Validation
Key parameters for method validation include:

